Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: Anti-CD20Fab-LDM

Gene Therapy

Volumn 17, Issue 10, 2010, Pages 1234-1243

  Xin, C ^a   Ye, S ^a   Ming, Y ^a   Shenghua, Z ^b   Qingfang, M ^b   Hongxing, G ^a   Xu, S ^a   Yuanfu, X ^a   Yuan, Z ^a   Dongmei, F ^a   Juanni, L ^a   Yingdai, G ^a   Lianfang, J ^b   Rongguang, S ^a   Zhenping, Z ^a   Jianxiang, W ^a   Tao, C ^a   Chunzheng, Y ^a   Dongsheng, X ^a,c   Yongsu, Z ^b  

^a Blood Diseases Hospital   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

anti CD20Fab LDM; B cell lymphoma; CD20; LDM; recombinant fusion protein

Indexed keywords

ANTIBIOTIC C 1027; ANTINEOPLASTIC AGENT; APOPROTEIN; CD20 ANTIBODY; CD20 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY CD 20 FAB FRAGMENT LIDAMYCIN FUSION PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER INHIBITION; CHROMATOPHORE; CONTROLLED STUDY; CYTOTOXICITY; DNA RECOMBINATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MOLECULAR GENETICS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENEDIYNES; FEMALE; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, NUDE; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 77958017905     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.76     Document Type: Article

References (27)

1. van de Loosdrecht AA, Huijgens PC, Ossenkoppele GJ. Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin's lymphoma. Curr Opin Hematol 2004; 11: 419-425.
2. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490-1496.
3. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-3254.
4. Hu JL, Xue YC, Xie MY, Zhang R, Otani T, Minami Yet al. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo) 1988; 41: 1575-1579.
5. Otani T, Minami Y, Marunaka T, Zhang R, Xie MY. A new macromolecular antitumor antibiotic C-1027. II. Isolation and physico-chemical properties. J Antibiot (Tokyo) 1988; 41: 1580-1585.
6. Zhen YS, Ming XY, Yu B, Otani T, Saito H, Yamada Y. A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity. J Antibiot (Tokyo) 1989; 42: 1294-1298.
7. Xu YJ, Li DD, Zhen YS. Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cyto-toxicity, on human hepatoma BEL-7402 cells. Cancer Chemother Pharmacol 1990; 27: 41-46.
8. Huang YH, Shang BY, Zhen YS. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule. World J Gastroenterol 2005; 11: 3980-3984.
9. Xu YJ, Zhen YS, Goldberg IH. C1027 chromophore, a potent new enediyne antitumor antibiotic, induces sequence-specific double-strand DNA cleavage. Biochemistry 1994; 33: 5947-5954.
10. McHugh MM, Gawron LS, Matsui S, Beerman TA. The anti-tumor enediyne C-1027 alters cell cycle progression and induces chromosomal aberrations and telomere dysfunction. Cancer Res 2005; 65: 5344-5351.
11. Jiang B, Li DD, Zhen YS. Induction of apoptosis by enediyne antitumor antibiotic C1027 in HL-60 human promyelocytic leukemia cells. Biochem Biophys Res Commun 1995; 208: 238-244.
12. 0 fragment on proliferation of B lymphoma cells. Chin Sci Bull 2001; 46: 5.
13. Sugimoto Y, Otani T, Oie S, Wierzba K, Yamada Y. Mechanism of action of a new macromolecular antitumor antibiotic, C-1027. J Antibiot (Tokyo) 1990; 43: 417-421.
14. Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol; 2006; 34; 753-759.
15. Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 2007; 13: 2392-2399.
16. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172: 3280-3288.
17. Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999; 18: 465-471.
18. Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006; 177: 7435-7443.
19. Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol 2007; 179: 4263-4271.
20. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176: 2600-2609.
21. Smith MR, Jin F, Joshi I. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Mol Cancer Ther 2004; 3: 1693-1699.
22. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma. Br J Haematol 2008; 143: 355-360.
23. Liu HZ, Li DD, Zhen YS, Shao RG. Potentiation and mechanism of cisplatin-induced apoptosis by lidamycin in human hepatoma BEL-7402 cells. Yao Xue Xue Bao 2003; 38: 250-254.
24. Tanaka T, Fukuda-Ishisaka S, Hirama M, Otani T. Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore. J Mol Biol 2001; 309: 267-283.
25. Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ et al. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 1998; 58: 3209-3214.
26. Qiu XQ, Wang H, Cai B, Wang LL, Yue ST. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol 2007; 25: 921-929.
27. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003; 7: 626-634.